Loading
A phase 1/2 trial of Golcadomide, Rituximab, Obinutuzumab in non-hodgkin lymphoma, run by Celgene, active and no longer recruiting.
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) is a phase 1/2 interventional study registered as NCT03930953 by Celgene, with 438 participants planned, started 2019-05-20 and due to reach its primary completion in 2027-04-07. Interventions recorded: CC-99282, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat. Conditions listed: Lymphoma, Non-Hodgkin. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Golcadomide, Obinutuzumab, Rituximab, Bristol Myers Squibb.
Shares Golcadomide, Rituximab, Bristol Myers Squibb, Non-Hodgkin lymphoma (all types).
Shares Golcadomide, Rituximab, Bristol Myers Squibb.
Shares Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).
Shares Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).
Shares Obinutuzumab, Rituximab.
Shares Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/